AiM Medical Robotics to Present and Exhibit at 18th Annual World Congress of Society for Brain Mapping and Therapeutics (SBMT)

Presentation by Dr. Julie Pilitsis, Chief Medical Advisor & Co-Founder, to take place on July 10th at 1:45 pm PST
Presentation by Dr. Greg Fischer, Chief Scientific Advisor & Co-Founder, to take place on July 11th at 4:45 pm PST

FORT LAUDERDALE, Fla., July 7, 2021 /PRNewswire/ — AiM Medical Robotics, a leading developer of MRI-safe intraoperative robotics for neurosurgery, today announced that they will be presenting and exhibiting at the prestigious 18th Annual World Congress of Society for Brain Mapping and Therapeutics (SBMT), which will be held in Los Angeles on July 8th – 11th. The program will be featuring state-of-the-art science and technology in the field of neuroscience and neurosurgery, and it will have close to 900 presenters and 10 keynotes.

The co-founders and inventors of AiM Medical Robotics, Dr. Greg Fischer of the Worcester Polytechnic Institute and Dr. Julie Pilitsis of the Albany Medical Center, will be presenting the latest updates on their NIH-funded research for brain tumor ablation during the SBMT scientific sessions. Additionally, Bob Cathcart, President & CEO of AiM Medical Robotics, and Dr. Jonathan Sackier, Director, will be meeting with clinicians and industry leaders during the Company’s exhibition at the Congress. 

“SBMT brings pioneers of neurosurgery and trailblazing companies together with game changing policy makers  in order to rapidly fast track diagnostics, devices and therapeutics for patients with neurological, spine and neuro-psychiatric disorders; AiM Medical Robotics is one of the leaders in the emerging field of artificial intelligence-guided therapy” said, Dr. Babak Kateb, founding chairman of the board of directors & CEO of SBMT, President and Scientific Director of the Brain Mapping Foundation, Director of National Center for Nano-Bio-Electronics, and Director of Brain Technology and Innovation Park.

Bob Cathcart commented, “We are extremely excited to have been asked to participate in this outstanding gathering of world leaders in Neurology. SBMT is at the forefront of discovery for the diagnosis and treatment of brain disorders. We are honored to have Dr. Fischer and Dr. Pilitsis participate in the scientific sessions to share their enthusiasm and the accomplishments that we have seen with our paradigm-shifting technology. Our MRI-compatible robotic system will give surgeons the ability to utilize MRI guidance for complex neurosurgical procedures. By combining the Real Time feedback of the MRI and the precision and accuracy of the robot, surgeons can confidently reach targets deep in the brain the first time every time.”

About AiM Medical Robotics

AiM Medical Robotics is a privately held biotechnology company currently focused on the development of MRI-compatible advanced robotics that are precision-focused and portable. You can follow AiM at www.aimmedrobotics.com and on LinkedIn at https://www.linkedin.com/company/aim-medical-robotics.   

Forward Looking Statements

This release may contain forward-looking statements that are subject to risks and uncertainties. Such forward-looking statements may include but are not necessarily limited to statements that relate to the advancement and development of the company’s robot or technologies, when used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon AiM Medical Robotics’ current expectations and various assumptions. AiM Medical Robotics believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. AiM Medical Robotics may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors.  Readers should not place undue reliance on the forward-looking statements, which reflect management’s view only as of the date hereof.  AiM Medical Robotics undertakes no obligation to publicly revise these forward-looking statements to reflect subsequent events or circumstances.

Contacts:
Bob Cathcart
Chief Executive Officer
AiM Medical Robotics, Inc.
(862) 703-0253
bcathcart@aimmedrobotics.com 

Investors:
Doug Nissinoff
Corporate Communications
AiM Medical Robotics, Inc.
(954) 204-6745
IR@aimmedrobotics.com